View Post

Clinical Challenges: When to Start End-of-Life Care in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Leah Lawrence From: medpagetoday.com Breast cancer remains the second leading cause of cancer death among women in the U.S. Although treatments for metastatic breast cancer — whether a new diagnosis or recurrent disease — have improved in recent years, metastatic disease remains incurable, explained Dawn L. Hershman, MD, MS, director of breast oncology at the Herbert Irving Comprehensive Cancer …

View Post

Tyme Technologies Begins Cancer Metabolism-Based Therapy Trial in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …

View Post

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: businesswire.com – Imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode’s TTX platform for delivery of RNA targeted therapy to metastatic solid tumors – — eIND submission for TTX-MC138 anticipated in 1Q 2022 to support Phase 0 study in metastatic solid tumors, designed to establish proof of concept for TTX delivery platform — TransCode …

View Post

Could Your Patient Benefit? New Clinical Trials in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Helen Leask From: medscape.com A number of phase 3 studies in breast cancer have opened in recent months. Maybe one of your patients could benefit from being enrolled? Advanced HER2+ breast cancer. Patients with previously treated advanced or metastatic HER2+ breast cancer with and without brain metastases are sought for the DESTINY-B12 trial of trastuzumab deruxtecan (Enhertu). Patients will …

View Post

Advanced imaging reveals breast cancer’s Achilles’ heel

In Clinical Studies News by Barbara Jacoby

Source: Garvan Institute of Medical Research From: eurekalert.org For breast cancer patients, standard-of care therapies become drastically less effective if their tumour has spread to other parts of the body, such as the lung. But a new treatment approach, investigated by a team at the Garvan Institute of Medical Research in experimental models, may help stop breast cancer cells right …

View Post

Value-Based Decision-Making in Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: managedhealthcareexecutive.com In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of …

View Post

AMEERA-1 and ER+/HER2- Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sarat Chandarlapaty, MD, PhD From: targetedonc.com Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer. Sarat Chandarlapaty, MD: The potential roles for amcenestrant could be a replacement of every place we use antiestrogen therapy in breast cancer. There’s potential for replacement of aromatase inhibitors, in the neoadjuvant …

View Post

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: MacroGenics From: pipelinereview.com Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS for trastuzumab plus chemotherapy was greater than MARGENZA plus chemotherapy for the small exploratory …

View Post

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

In Clinical Studies News by Barbara Jacoby

Source: PharmAbcine From: prnewswire.com PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II combination trial of olinvacimab, PharmAbcine’s anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) in …

View Post

Jemperli

In Clinical Studies News by Barbara Jacoby

From: breastcancer.org Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available. Jemperli also is approved to treat dMMR advanced-stage endometrial cancer that has grown after treatment with platinum chemotherapy. How Jemperli works …